Anthrax infection
diseaseOn this page
Also known as anthraxBacillus anthracis caused disease or disorderBacillus anthracis disease or disorderBacillus anthracis infectious disease
Summary
Anthrax infection (MONDO:0005119) is a disease and 34 clinical trials. Top therapeutic interventions include ciprofloxacin, obiltoxaximab, and bacillus anthracis protective antigen, adsorbed. A subtype of primary bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 34
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anthrax infection |
| Mondo ID | MONDO:0005119 |
| EFO | EFO:0000778 |
| MeSH | D000881 |
| DOID | DOID:7427 |
| ICD-10-CM | A22 |
| NCIT | C84565 |
| SNOMED CT | 409498004 |
| UMLS | C0003175 |
| MedGen | 8110 |
| GARD | 0008157 |
| Is cancer (heuristic) | no |
Also known as: anthrax · Bacillus anthracis caused disease or disorder · Bacillus anthracis disease or disorder · Bacillus anthracis infectious disease
Disease family
This is a subtype of primary bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › anthrax infection
Related subtypes (36): Buruli ulcer disease, sennetsu fever, salmonellosis, pinta disease, chancroid, gonorrhea, leprosy, botulism, diphtheria, tetanus, bartonellosis, brucellosis, campylobacteriosis, glanders, granuloma inguinale, legionellosis, leptospirosis, listeriosis, Mycobacterium avium complex disease, ornithosis, rhinoscleroma, staphyloenterotoxemia, syphilis, cholera, ehrlichiosis, melioidosis, tuberculosis, tularemia, plague, Q fever, shigellosis, Lyme disease, relapsing fever, spirillary rat-bite fever, streptobacillary rat-bite fever, Borrelia miyamotoi disease
Subtypes (4): gastrointestinal anthrax, cutaneous anthrax, inhalational anthrax, injection anthrax
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Bacillus Anthracis Protective Antigen, Adsorbed | Approved (phase 4) |
| Obiltoxaximab | Approved (phase 4) |
| Raxibacumab | Approved (phase 4) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aluminum Hydroxide, Ciprofloxacin.
Clinical trials & evidence
Clinical trials
Clinical trials: 34.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 14 |
| Not specified | 9 |
| PHASE2 | 7 |
| PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03088111 | PHASE4 | UNKNOWN | An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis |
| NCT01491607 | PHASE3 | COMPLETED | Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults |
| NCT03877926 | PHASE3 | COMPLETED | VELOCITY: An Anthrax Vaccine Clinical Study |
| NCT05997264 | PHASE2 | ACTIVE_NOT_RECRUITING | Anthrax AV7909 Boost Evaluation Study |
| NCT00100724 | PHASE2 | COMPLETED | Trial of rPA-102 Vaccine in Healthy Adult Volunteers |
| NCT00845650 | PHASE1/PHASE2 | COMPLETED | Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) |
| NCT01624532 | PHASE2 | COMPLETED | A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 |
| NCT01753115 | PHASE2 | COMPLETED | Ciprofloxacin BioThrax Co-Administration Study |
| NCT01770743 | PHASE2 | COMPLETED | A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels |
| NCT03518125 | PHASE2 | COMPLETED | BARDA Securing Anthrax Immunity For the Elderly |
| NCT04067011 | PHASE2 | COMPLETED | Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study |
| NCT00057525 | PHASE1 | COMPLETED | A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults |
| NCT00063843 | PHASE1 | COMPLETED | Anthrax-rPA: Safety, Tolerability, Immunogenicity |
| NCT00114621 | PHASE1 | COMPLETED | Anthrax Vaccine Clinical Trials |
| NCT00964561 | PHASE1 | SUSPENDED | Ph1 Study of Valortim and Ciprofloxacin in Humans |
| NCT00964834 | PHASE1 | TERMINATED | Ph1 Study of Valortim and Doxycycline in Humans |
| NCT01202695 | PHASE1 | COMPLETED | Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) |
| NCT01265745 | PHASE1 | COMPLETED | Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects |
| NCT01453907 | PHASE1 | COMPLETED | Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers |
| NCT01867957 | PHASE1 | COMPLETED | Efficacy and Safety of Anthrax Vaccine, GC1109 |
| NCT01979406 | PHASE1 | COMPLETED | A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines |
| NCT02239172 | PHASE1 | COMPLETED | PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine |
| NCT02655549 | PHASE1 | COMPLETED | A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects |
| NCT04148118 | PHASE1 | COMPLETED | A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults |
| NCT04660201 | PHASE1 | COMPLETED | Anthrax AV7909 Liquid vs Lyophilized |
| NCT00050310 | Not specified | RECRUITING | Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients |
| NCT03569514 | Not specified | NOT_YET_RECRUITING | Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax |
| NCT07268612 | Not specified | NOT_YET_RECRUITING | Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. |
| NCT00031291 | Not specified | COMPLETED | Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin |
| NCT00123396 | Not specified | COMPLETED | VHA Clinicians and Bioterror Events: Interactive Web-based Learning |
| NCT03498027 | Not specified | COMPLETED | Febrile Whole Blood Specimen Collection and Testing |
| NCT04320485 | Not specified | COMPLETED | Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI) |
| NCT05672875 | Not specified | TERMINATED | Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System |
| NCT06365073 | Not specified | UNKNOWN | A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CIPROFLOXACIN | 4 | 2 |
| OBILTOXAXIMAB | 4 | 2 |
| BACILLUS ANTHRACIS PROTECTIVE ANTIGEN, ADSORBED | 4 | 1 |
| HUMAN IMMUNOGLOBULIN G | 4 | 1 |
| MDX-1303 | 1 | 2 |
| AVP-21D9 | 1 | 1 |